Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.

Saiki M, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Nishio M.

Lung Cancer. 2019 Jul;133:4-9. doi: 10.1016/j.lungcan.2019.04.022. Epub 2019 Apr 27.

PMID:
31200826
2.

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.

Kawashima Y, Nishikawa S, Ninomiya H, Yoshida R, Takano N, Oguri T, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ishikawa Y, Nishio M.

Intern Med. 2019;58(10):1479-1484. doi: 10.2169/internalmedicine.1673-18. Epub 2019 May 15.

3.

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.

Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M.

Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21.

PMID:
31027701
4.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
5.

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.

Sonoda T, Nishikawa S, Sakakibara R, Saiki M, Ariyasu R, Koyama J, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ninomiya H, Ishikawa Y, Nishio M.

Respir Med Case Rep. 2018 Mar 16;24:19-21. doi: 10.1016/j.rmcr.2018.03.009. eCollection 2018.

6.

Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.

Saiki M, Kitazono S, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Yanagitani N, Horiike A, Ohyanagi F, Oikado K, Ninomiya H, Takeuchi K, Ishikawa Y, Nishio M.

Clin Lung Cancer. 2018 Sep;19(5):435-440.e1. doi: 10.1016/j.cllc.2018.04.006. Epub 2018 May 10.

PMID:
29885946
7.

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R.

Lung Cancer. 2018 Mar;117:1-6. doi: 10.1016/j.lungcan.2017.12.018. Epub 2018 Jan 4.

PMID:
29496249
8.

Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.

Saiki M, Ohyanagi F, Ariyasu R, Koyama J, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Ninomiya H, Ishikawa Y, Nishio M.

Jpn J Clin Oncol. 2017 Dec 1;47(12):1189-1192. doi: 10.1093/jjco/hyx133.

PMID:
28977547
9.

Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.

Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M.

Anticancer Res. 2017 Aug;37(8):4229-4232.

PMID:
28739711
10.

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.

Ariyasu R, Horiike A, Koyama J, Saiki M, Sonoda T, Kawashima Y, Takano N, Oguri T, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Nishio M.

Anticancer Drugs. 2017 Jun;28(5):565-567. doi: 10.1097/CAD.0000000000000489.

PMID:
28225456
11.

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.

Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Matsuura Y, Nakao M, Mun M, Okumura S, Inase N, Nishio M, Motoi N, Ishikawa Y.

Clin Lung Cancer. 2017 Sep;18(5):527-534.e1. doi: 10.1016/j.cllc.2016.12.002. Epub 2016 Dec 22.

PMID:
28111119
12.

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.

Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Hozumi H, Tamura T.

Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct 20.

13.

A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.

Nishikawa S, Tambo Y, Ninomiya H, Oguri T, Kawashima Y, Takano N, Kitazono S, Ohyanagi F, Horiike A, Yanagitani N, Ishikawa Y, Nishio M.

Ann Oncol. 2016 Dec;27(12):2300-2302. doi: 10.1093/annonc/mdw431. Epub 2016 Oct 19. No abstract available.

PMID:
27760736
14.

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.

Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M.

Invest New Drugs. 2017 Feb;35(1):37-46. doi: 10.1007/s10637-016-0382-3. Epub 2016 Aug 27.

PMID:
27565810
15.

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.

EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.

16.

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.

Nokihara H, Yamada Y, Fujiwara Y, Yamamoto N, Wakui H, Nakamichi S, Kitazono S, Inoue K, Harada A, Taube T, Takeuchi Y, Tamura T.

Invest New Drugs. 2016 Feb;34(1):66-74. doi: 10.1007/s10637-015-0300-0. Epub 2015 Dec 2.

PMID:
26627079
17.

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).

Mizugaki H, Yamamoto N, Nokihara H, Fujiwara Y, Horinouchi H, Kanda S, Kitazono S, Yagishita S, Xiong H, Qian J, Hashiba H, Shepherd SP, Giranda V, Tamura T.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1063-72. doi: 10.1007/s00280-015-2876-7. Epub 2015 Oct 3.

18.

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y.

Clin Lung Cancer. 2015 Sep;16(5):385-90. doi: 10.1016/j.cllc.2015.03.008. Epub 2015 Apr 4.

PMID:
25937270
19.

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.

Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T.

Invest New Drugs. 2015 Aug;33(4):881-9. doi: 10.1007/s10637-015-0243-5. Epub 2015 May 1.

20.

A phase I study of resminostat in Japanese patients with advanced solid tumors.

Kitazono S, Fujiwara Y, Nakamichi S, Mizugaki H, Nokihara H, Yamamoto N, Yamada Y, Inukai E, Nakamura O, Tamura T.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1155-61. doi: 10.1007/s00280-015-2741-8. Epub 2015 Apr 7.

PMID:
25847480
21.

Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.

Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, Kitamura Y, Shimoyama T, Maeda Y, Takahashi F, Takahashi K, Tamura T, Koizumi F.

Mol Cancer Ther. 2015 Jun;14(6):1414-23. doi: 10.1158/1535-7163.MCT-14-0625. Epub 2015 Apr 1.

22.

Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.

Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Fujiwara Y, Tamura Y, Wakui H, Honda K, Mizugaki H, Kitazono S, Tanabe Y, Asahina H, Yamazaki N, Suzuki S, Matsuoka M, Ogita Y, Tamura T.

Invest New Drugs. 2015 Jun;33(3):641-51. doi: 10.1007/s10637-015-0229-3. Epub 2015 Mar 27.

PMID:
25809858
23.

Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.

Yagishita S, Horinouchi H, Katsui Taniyama T, Nakamichi S, Kitazono S, Mizugaki H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):140-8. doi: 10.1016/j.ijrobp.2014.08.344. Epub 2014 Oct 13.

PMID:
25442336
24.

Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.

Mizugaki H, Fujiwara Y, Yamamoto N, Yagishita S, Kitazono S, Tanaka A, Horinouchi H, Kanda S, Nokihara H, Tsuta K, Asamura H, Tamura T.

Jpn J Clin Oncol. 2014 Sep;44(9):835-40. doi: 10.1093/jjco/hyu092. Epub 2014 Aug 5.

PMID:
25097183
25.

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.

Wakui H, Yamamoto N, Kitazono S, Mizugaki H, Nakamichi S, Fujiwara Y, Nokihara H, Yamada Y, Suzuki K, Kanda H, Akinaga S, Tamura T.

Cancer Chemother Pharmacol. 2014 Jul;74(1):15-23. doi: 10.1007/s00280-014-2467-z. Epub 2014 Apr 22.

PMID:
24752449
26.

Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer.

Yagishita S, Horinouchi H, Yorozu T, Kitazono S, Mizugaki H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Mori T, Tsuta K, Sumi M, Tamura T.

Jpn J Clin Oncol. 2014 Feb;44(2):191-4. doi: 10.1093/jjco/hyt192. Epub 2013 Dec 13.

PMID:
24338556
27.

Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.

Kitazono S, Takiguchi Y, Ashinuma H, Saito-Kitazono M, Kitamura A, Chiba T, Sakaida E, Sekine I, Tada Y, Kurosu K, Sakao S, Tanabe N, Iwama A, Yokosuka O, Tatsumi K.

Int J Oncol. 2013 Dec;43(6):1846-54. doi: 10.3892/ijo.2013.2120. Epub 2013 Oct 3.

28.

Antiproliferative action of metformin in human lung cancer cell lines.

Ashinuma H, Takiguchi Y, Kitazono S, Kitazono-Saitoh M, Kitamura A, Chiba T, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Iwama A, Yokosuka O, Tatsumi K.

Oncol Rep. 2012 Jul;28(1):8-14. doi: 10.3892/or.2012.1763. Epub 2012 Apr 18.

PMID:
22576795
29.

Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.

Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Tagawa M, Tatsumi K.

Oncol Rep. 2012 Jul;28(1):33-40. doi: 10.3892/or.2012.1799. Epub 2012 May 4.

PMID:
22562354
30.

A case of isolated peripheral pulmonary artery branch stenosis associated with multiple pulmonary artery aneurysms.

Amano H, Tanabe N, Sakao S, Umekita H, Sugiura T, Kitazono S, Kitazono M, Kuroda F, Kasahara Y, Tatsumi K.

Intern Med. 2010;49(17):1895-9. Epub 2010 Sep 1.

31.

[Symptomatic splenomegaly in a young Japanese man with sarcoidosis accompanied by spleen, liver, kidney, lung and lymph node lesions].

Kitamura A, Takiguchi Y, Sugiura T, Kitazono S, Kurosu K, Tanabe N, Kisimoto T, Tatsumi K.

Nihon Kokyuki Gakkai Zasshi. 2009 Aug;47(8):742-5. Japanese.

PMID:
19764520
32.

[A case of the temporomandibular arthritis during the orthodontic treatment].

Kitazono S, Watanabe H, Kido K, Matsumoto M, Shimoda T, Honda T, Yuuda T.

Fukuoka Shika Daigaku Gakkai Zasshi. 1990;17(4):423-33. Japanese.

PMID:
2135056
33.

Nonimmunologic hydrops fetalis: a clinicopathological study of 50 autopsy cases.

Nakamura Y, Komatsu Y, Yano H, Kitazono S, Hosokawa Y, Fukuda S, Kawano S, Nagasue N, Matsunaga T, Aiko Y, et al.

Pediatr Pathol. 1987;7(1):19-30.

PMID:
3601817
34.

[A histopathological study of the ensuing repair processes of the condyle and the effect on mandibular growth after chondroectomy].

Itoh A, Kitazono S, Matsumoto Y, Kiyama K, Taniguchi K, Koh Y, Nakao N, Kitamura K.

Nihon Kyosei Shika Gakkai Zasshi. 1986 Mar;45(1):73-83. Japanese. No abstract available.

PMID:
3458850
35.

[Orthodontic treatment for 3 impacted upper anterior teeth].

Matsumoto Y, Kitazono S, Ohtsuru Y, Himeno R.

Fukuoka Shika Daigaku Gakkai Zasshi. 1986;13(1):60-6. Japanese. No abstract available.

PMID:
3464461

Supplemental Content

Loading ...
Support Center